Oxford develops Ebola vaccine in eight weeks, begins first human trials as Congo outbreak spreads

Reuters—Researchers at Oxford University have begun the first human clinical trial of a new Ebola vaccine developed in just eight weeks, targeting the Bundibugyo strain. The accelerated timeline reflects advances in rapid-response vaccine technology and the urgency of the ongoing Democratic Republic of Congo outbreak, which has spread to multiple provinces. The trial is being conducted in the UK with healthy volunteers. If successful, it could provide a new tool to contain the DRC outbreak or future Ebola crises.

• Reuters — Oxford leads the trial; vaccine targets the Bundibugyo Ebola strain specifically
• Sky News — Human trials began in the UK with healthy volunteers receiving the first doses of the experimental vaccine
• BBC — Health — Vaccine developed at Oxford using rapid-response technology adapted from approaches used in the COVID era
• BBC — Development-to-trial timeline of eight weeks is among the fastest on record for any Ebola vaccine candidate